Post-Operative Pain-Pipeline Review, H1 2015

Post-Operative Pain-Pipeline Review, H1 2015

  • Products Id :- GMDHC6116IDB
  • |
  • Pages: 165
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Post-Operative Pain-Pipeline Review, H1 2015


Global Markets Direct's, 'Post-Operative Pain-Pipeline Review, H1 2015', provides an overview of the Post-Operative Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Post-Operative Pain Overview 11

Therapeutics Development 12

Pipeline Products for Post-Operative Pain-Overview 12

Pipeline Products for Post-Operative Pain-Comparative Analysis 13

Post-Operative Pain-Therapeutics under Development by Companies 14

Post-Operative Pain-Therapeutics under Investigation by Universities/Institutes 17

Post-Operative Pain-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Post-Operative Pain-Products under Development by Companies 21

Post-Operative Pain-Products under Investigation by Universities/Institutes 23

Post-Operative Pain-Companies Involved in Therapeutics Development 24

A. Menarini Industrie Farmaceutiche Riunite Srl 24

AcelRx Pharmaceuticals, Inc. 25

Adynxx, Inc. 26

AngioChem Inc. 27

Boehringer Ingelheim GmbH 28

Cara Therapeutics, Inc. 29

Chong Kun Dang Pharmaceutical Corp. 30

Cytogel Pharma, LLC 31

DURECT Corporation 32

Echo Pharmaceuticals B.V. 33

Encore Therapeutics Inc. 34

Flexion Therapeutics, Inc. 35

Galleon Pharmaceuticals 36

Grunenthal GmbH 37

GW Pharmaceuticals plc 38

Heron Therapeutics, Inc. 39

Immupharma Plc 40

INSYS Therapeutics, Inc. 41

Laboratorios Del Dr. Esteve S.A. 42

Medtronic, Inc. 43

Ocular Therapeutix, Inc. 44

Omeros Corporation 45

Orbis Biosciences, Inc. 46

Orion Oyj 47

Pharmazz, Inc. 48

PhytoHealth Corporation 49

Recro Pharma, Inc. 50

Rottapharm SpA 51

Takeda Pharmaceutical Company Limited 52

Thar Pharmaceuticals, Inc. 53

Trevena, Inc. 54

UMeWorld Limited 55

Post-Operative Pain-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Combination Products 57

Assessment by Target 58

Assessment by Mechanism of Action 60

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

(bupivacaine hydrochloride + meloxicam)-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

(dexketoprofen trometamol + tramadol hydrochloride)-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

(ketoprofen + amitriptyline + oxymetazoline)-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

(ketorolac tromethamine + phenylephrine hydrochloride)-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

AM-4-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

ANG-2002-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

ARX-01-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

ARX-8028-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

ARX-8203-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

AYX-1-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

BI-1026706-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

bupivacaine hydrochloride-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

bupivacaine hydrochloride liposomal-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

bupivacaine hydrochloride SR-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

buprenorphine hydrochloride-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

centhaquine-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

CKD-943-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

CMX-020-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

CR-4056-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

CR-845-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Cyt-1010-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

dexamethasone acetate SR-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

dexmedetomidine hydrochloride-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

dronabinol-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

E-52862-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

fadolmidine hydrochloride-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

FX-007-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

GAL-044-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

GIBH-1014-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

grapiprant-Drug Profile 109

Product Description 109

Mechanism of Action 109

R&D Progress 109

IPP-102199-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

ketamine hydrochloride ER-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

MDT-10013-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

nabiximols-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

nalbuphine hydrochloride-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

ropivacaine-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

ropivacaine ER-Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

T-109-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

tapentadol hydrochloride-Drug Profile 122

Product Description 122

Mechanism of Action 122

R&D Progress 122

tramadol hydrochloride-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

TRV-130-Drug Profile 124

Product Description 124

Mechanism of Action 124

R&D Progress 124

VVZ-149-Drug Profile 125

Product Description 125

Mechanism of Action 125

R&D Progress 125

Post-Operative Pain-Recent Pipeline Updates 126

Post-Operative Pain-Dormant Projects 153

Post-Operative Pain-Discontinued Products 155

Post-Operative Pain-Product Development Milestones 156

Featured News & Press Releases 156

Nov 17, 2014: Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain 156

Oct 30, 2014: Omidria Granted Pass-Through Reimbursement Status from CMS 158

Oct 08, 2014: Ocular Therapeutix Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain 158

Oct 08, 2014: Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain 159

Sep 16, 2014: Trevena Granted Key U.S. Composition of Matter Patent for TRV130 159

Sep 04, 2014: Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN 159

Jul 16, 2014: Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain 160

May 14, 2014: Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program 161

May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 161

May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 162

Appendix 164

Methodology 164

Coverage 164

Secondary Research 164

Primary Research 164

Expert Panel Validation 164

Contact Us 165

Disclaimer 165

List of Tables

Number of Products under Development for Post-Operative Pain, H1 2015 12

Number of Products under Development for Post-Operative Pain-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Investigation by Universities/Institutes, H1 2015 23

Post-Operative Pain-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 24

Post-Operative Pain-Pipeline by AcelRx Pharmaceuticals, Inc., H1 2015 25

Post-Operative Pain-Pipeline by Adynxx, Inc., H1 2015 26

Post-Operative Pain-Pipeline by AngioChem Inc., H1 2015 27

Post-Operative Pain-Pipeline by Boehringer Ingelheim GmbH, H1 2015 28

Post-Operative Pain-Pipeline by Cara Therapeutics, Inc., H1 2015 29

Post-Operative Pain-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 30

Post-Operative Pain-Pipeline by Cytogel Pharma, LLC, H1 2015 31

Post-Operative Pain-Pipeline by DURECT Corporation, H1 2015 32

Post-Operative Pain-Pipeline by Echo Pharmaceuticals B.V., H1 2015 33

Post-Operative Pain-Pipeline by Encore Therapeutics Inc., H1 2015 34

Post-Operative Pain-Pipeline by Flexion Therapeutics, Inc., H1 2015 35

Post-Operative Pain-Pipeline by Galleon Pharmaceuticals, H1 2015 36

Post-Operative Pain-Pipeline by Grunenthal GmbH, H1 2015 37

Post-Operative Pain-Pipeline by GW Pharmaceuticals plc, H1 2015 38

Post-Operative Pain-Pipeline by Heron Therapeutics, Inc., H1 2015 39

Post-Operative Pain-Pipeline by Immupharma Plc, H1 2015 40

Post-Operative Pain-Pipeline by INSYS Therapeutics, Inc., H1 2015 41

Post-Operative Pain-Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 42

Post-Operative Pain-Pipeline by Medtronic, Inc., H1 2015 43

Post-Operative Pain-Pipeline by Ocular Therapeutix, Inc., H1 2015 44

Post-Operative Pain-Pipeline by Omeros Corporation, H1 2015 45

Post-Operative Pain-Pipeline by Orbis Biosciences, Inc., H1 2015 46

Post-Operative Pain-Pipeline by Orion Oyj, H1 2015 47

Post-Operative Pain-Pipeline by Pharmazz, Inc., H1 2015 48

Post-Operative Pain-Pipeline by PhytoHealth Corporation, H1 2015 49

Post-Operative Pain-Pipeline by Recro Pharma, Inc., H1 2015 50

Post-Operative Pain-Pipeline by Rottapharm SpA, H1 2015 51

Post-Operative Pain-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 52

Post-Operative Pain-Pipeline by Thar Pharmaceuticals, Inc., H1 2015 53

Post-Operative Pain-Pipeline by Trevena, Inc., H1 2015 54

Post-Operative Pain-Pipeline by UMeWorld Limited, H1 2015 55

Assessment by Monotherapy Products, H1 2015 56

Assessment by Combination Products, H1 2015 57

Number of Products by Stage and Target, H1 2015 59

Number of Products by Stage and Mechanism of Action, H1 2015 61

Number of Products by Stage and Route of Administration, H1 2015 63

Number of Products by Stage and Molecule Type, H1 2015 65

Post-Operative Pain Therapeutics-Recent Pipeline Updates, H1 2015 126

Post-Operative Pain-Dormant Projects, H1 2015 153

Post-Operative Pain-Discontinued Products, H1 2015 155

List of Figures

Number of Products under Development for Post-Operative Pain, H1 2015 12

Number of Products under Development for Post-Operative Pain-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 56

Assessment by Combination Products, H1 2015 57

Number of Products by Top 10 Targets, H1 2015 58

Number of Products by Stage and Top 10 Targets, H1 2015 58

Number of Products by Top 10 Mechanism of Actions, H1 2015 60

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 60

Number of Products by Top 10 Routes of Administration, H1 2015 62

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 62

Number of Products by Top 10 Molecule Types, H1 2015 64

Number of Products by Stage and Top 10 Molecule Types, H1 2015 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

A. Menarini Industrie Farmaceutiche Riunite Srl

AcelRx Pharmaceuticals, Inc.

Adynxx, Inc.

AngioChem Inc.

Boehringer Ingelheim GmbH

Cara Therapeutics, Inc.

Chong Kun Dang Pharmaceutical Corp.

Cytogel Pharma, LLC

DURECT Corporation

Echo Pharmaceuticals B.V.

Encore Therapeutics Inc.

Flexion Therapeutics, Inc.

Galleon Pharmaceuticals

Grunenthal GmbH

GW Pharmaceuticals plc

Heron Therapeutics, Inc.

Immupharma Plc

INSYS Therapeutics, Inc.

Laboratorios Del Dr. Esteve S.A.

Medtronic, Inc.

Ocular Therapeutix, Inc.

Omeros Corporation

Orbis Biosciences, Inc.

Orion Oyj

Pharmazz, Inc.

PhytoHealth Corporation

Recro Pharma, Inc.

Rottapharm SpA

Takeda Pharmaceutical Company Limited

Thar Pharmaceuticals, Inc.

Trevena, Inc.

UMeWorld Limited

Post-Operative Pain Therapeutic Products under Development, Key Players in Post-Operative Pain Therapeutics, Post-Operative Pain Pipeline Overview, Post-Operative Pain Pipeline, Post-Operative Pain Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]